Shares of biotech company Biogen were moving higher on Thursday after the company received an upgrade from an analyst. RBC Capital Markets analyst Brian Abrahams upgraded Biogen stock on hopes for its Alzheimer’s drugs. Abrahams sees an $8 billion peak opportunity if the CMS decision comes out in Aduhelm’s favor and if Biogen succeeds with … Continue reading “Biogen Gets Analyst Upgrade and Announces Layoffs”
Tag: aduhelm
Biotech & Pharma
Biogen Shares Fall as Medicare Proposal Restricts Alzheimer’s Treatment Coverage
Shares of Biogen were falling this week after the U.S. Medicare program's proposal to severely…
January 14, 2022
Biotech & Pharma
Biogen Shares Explode on FDA Approval of Alzheimer’s Drug
Shares of biotech company Biogen were soaring on Monday after Wall Street learned that the…
June 7, 2021